Tüdőrák: vizsgálatok itt: Egyesült Királyság
153 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisFut, nem toborozStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Edinburgh, London, Manchester
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Cambridge, London, Newcastle upon Tyne, Northwood, Oxford
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - 3. fázisBefejeződöttA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Aberdeen, Central Middlesbrough, Manchester, Metropolitan Borough of Wirral
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - 3. fázisTaking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- London, Portsmouth, Truro
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - 3. fázisTaking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00 - 3. fázisTaking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Cardiff, Leicester, Manchester, Sutton, Torquay
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - 1. fázisNot yet taking people in Egyesült KirályságA Study of LY4336619 in Adult Participants With Advanced Solid Tumors
- Where
- Manchester, Sutton
- Életkor
- 18 év and over
- People
- 370 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00 - 3. fázisTaking peopleA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Dundee, Exeter, Glasgow, Larbert, Leicester, London, Manchester, Metropolitan Borough of Wirral, Reading
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - 2. fázisTaking peopleBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Where
- Leeds, London, Sutton
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- London
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Edinburgh, London, Manchester, Sutton
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 3. fázisFut, nem toborozStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Birmingham, Liverpool, London, Manchester, Nottingham, Sutton
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00 - No phaseTaking peopleA Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- Where
- Birmingham, Guildford, Leeds, Middlesbrough, Norfolk
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07284121 - 1/2. fázisTaking peopleA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Glasgow, London
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford, Stoke-on-Trent, Sutton
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - 1. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- London, Manchester
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- London, Manchester
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - 3. fázisTaking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne, Sutton
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Where
- Sutton
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00 - 1/2. fázisTaking peopleA 2-part Phase 1/2 Open-label Trial on ODM-212
- Where
- Leicester, London, Southampton
- Életkor
- 18 év and over
- People
- 229 worldwide
- Run by
- Orion Corporation, Orion Pharma
See details and how to joinNCT07563738 - 3. fázisTaking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
- Életkor
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - 3. fázisVisszavonvaA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Belfast, Cardiff, Guildford, Torquay
- Életkor
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- London, Manchester
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 3. fázisTaking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - 2. fázisTaking peopleA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00